Nebula Research & Development LLC Revance Therapeutics, Inc. Transaction History

Nebula Research & Development LLC

  • $836 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$2.34 - $4.73 $71,374 - $144,274
-30,502 Reduced 17.44%
144,365 $371 Million
Q1 2024

May 15, 2024
BUY
$4.65 - $9.31 $323,509 - $647,715
69,572 Added 66.07%
174,867 $860 Million
Q4 2023

Feb 14, 2024
BUY
$5.81 - $11.2 $611,763 - $1.18 Million
105,295 New
105,295 $926 Million
Q2 2023

Aug 14, 2023
BUY
$24.7 - $37.61 $286,989 - $436,990
11,619 New
11,619 $294 Million

Others Institutions Holding RVNC

# of Institutions
234
Shares Held
82.8M
Call Options Held
680K
Put Options Held
896K
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Nebula Research & Development LLC Portfolio

Follow Nebula Research & Development LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nebula Research & Development LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nebula Research & Development LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email